We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna Brings AI to Specialty Pharmacy With Pharmacy Forward
Read MoreHide Full Article
Key Takeaways
CI is rolling out Pharmacy Forward through Accredo to simplify specialty pharmacy with AI.
Cigna expects faster prescription processing, lower admin work and stronger medication adherence.
Evernorth's Q1 2026 adjusted revenues rose 9%, while Specialty and Care Services earnings grew 20%.
The Cigna Group’s (CI - Free Report) health services division, Evernorth, has launched Pharmacy Forward, an AI-powered specialty pharmacy initiative designed to simplify and accelerate the prescription journey for patients with complex conditions. Backed by a $100 million investment through 2028, the program will first roll out through Accredo Specialty Pharmacy. By using artificial intelligence across prescription intake, clinical support and fulfilment, the platform aims to reduce delays, improve communication and help patients start treatment sooner.
The platform is expected to make specialty pharmacy operations more efficient for both patients and healthcare providers. Pharmacy Forward is projected to cut prescription processing times in half while reducing clinicians' administrative work. It also expands personalized digital support to improve medication adherence. Another advantage is its logistics network, with 90% of Accredo patients living within a one-day ground delivery radius. The initiative is expected to generate nearly $400 million in cumulative value by the end of 2028.
The launch fits into Cigna's broader plan to expand Evernorth Health Services, a key growth driver. The company has been investing in technology to simplify pharmacy services, improve efficiency and encourage biosimilar adoption. The strategy is already showing results. In the first quarter of 2026, Evernorth's adjusted revenues rose 9% year over year to $58.4 billion, while pretax adjusted earnings in its Specialty and Care Services business increased 20%.
Pharmacy Forward highlights Cigna's continued push to grow its healthcare services business beyond traditional insurance. Although the investment is unlikely to have a meaningful impact on near-term earnings, it could strengthen Evernorth's position in the growing specialty pharmacy market by improving efficiency and patient experience. Combined with higher adjusted EPS guidance for 2026 and the leadership of CEO Brian Evanko, the initiative reinforces Cigna's long-term growth strategy.
Cigna’s Stock Price Performance
Shares of Cigna have gained 0.7% year to date compared with the industry’s 25.2% gain over the same period.
The Zacks Consensus Estimate for UnitedHealth Group’s 2026 earnings is pegged at $18.32 per share, indicating 12.05% year-over-year growth. UNH beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 0.8%. The consensus estimate for 2026 revenues is pinned at $443.7 billion.
The Zacks Consensus Estimate for Elevance Health’s 2026 earnings is pegged at $26.86 per share, which has witnessed one upward revision in the past 30 days, with no movement in the opposite direction. ELV beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 10.6%. The consensus estimate for 2026 revenues is pinned at $ 194.24 billion.
The Zacks Consensus Estimate for CVS Health’s 2026 earnings is pegged at $7.44 per share, indicating 10.22% year-over-year growth. CVS beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.8%. The consensus estimate for 2026 revenues is pinned at $409 billion, implying 1.7% year-over-year growth.
View the Zacks #1 Rank List
Image: Bigstock
Cigna Brings AI to Specialty Pharmacy With Pharmacy Forward
Key Takeaways
The Cigna Group’s (CI - Free Report) health services division, Evernorth, has launched Pharmacy Forward, an AI-powered specialty pharmacy initiative designed to simplify and accelerate the prescription journey for patients with complex conditions. Backed by a $100 million investment through 2028, the program will first roll out through Accredo Specialty Pharmacy. By using artificial intelligence across prescription intake, clinical support and fulfilment, the platform aims to reduce delays, improve communication and help patients start treatment sooner.
The platform is expected to make specialty pharmacy operations more efficient for both patients and healthcare providers. Pharmacy Forward is projected to cut prescription processing times in half while reducing clinicians' administrative work. It also expands personalized digital support to improve medication adherence. Another advantage is its logistics network, with 90% of Accredo patients living within a one-day ground delivery radius. The initiative is expected to generate nearly $400 million in cumulative value by the end of 2028.
The launch fits into Cigna's broader plan to expand Evernorth Health Services, a key growth driver. The company has been investing in technology to simplify pharmacy services, improve efficiency and encourage biosimilar adoption. The strategy is already showing results. In the first quarter of 2026, Evernorth's adjusted revenues rose 9% year over year to $58.4 billion, while pretax adjusted earnings in its Specialty and Care Services business increased 20%.
Pharmacy Forward highlights Cigna's continued push to grow its healthcare services business beyond traditional insurance. Although the investment is unlikely to have a meaningful impact on near-term earnings, it could strengthen Evernorth's position in the growing specialty pharmacy market by improving efficiency and patient experience. Combined with higher adjusted EPS guidance for 2026 and the leadership of CEO Brian Evanko, the initiative reinforces Cigna's long-term growth strategy.
Cigna’s Stock Price Performance
Shares of Cigna have gained 0.7% year to date compared with the industry’s 25.2% gain over the same period.
Image Source: Zacks Investment Research
Cigna’s Zacks Rank & Key Picks
CI currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Medical space are UnitedHealth Group Incorporated (UNH - Free Report) , Elevance Health, Inc. (ELV - Free Report) and CVS Health Corporation (CVS - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for UnitedHealth Group’s 2026 earnings is pegged at $18.32 per share, indicating 12.05% year-over-year growth. UNH beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 0.8%. The consensus estimate for 2026 revenues is pinned at $443.7 billion.
The Zacks Consensus Estimate for Elevance Health’s 2026 earnings is pegged at $26.86 per share, which has witnessed one upward revision in the past 30 days, with no movement in the opposite direction. ELV beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 10.6%. The consensus estimate for 2026 revenues is pinned at $ 194.24 billion.
The Zacks Consensus Estimate for CVS Health’s 2026 earnings is pegged at $7.44 per share, indicating 10.22% year-over-year growth. CVS beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.8%. The consensus estimate for 2026 revenues is pinned at $409 billion, implying 1.7% year-over-year growth.